Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Index funds typically provide lower fees and simpler index tracking compared to mutual funds, making them a popular choice for new investors.
22,898 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Tempo, the stripe-backed crypto startup, launches a cross-chain AI payments protocol and goes live with its Tempo blo...
Freddie Mac data show mortgage rates climbed to their highest level in almost four months, pushing the 30-year loan t...
A biotech stock that surged 135% in a year suddenly sees a big investor trim its stake by about $44 million. Here’s h...
Kentucky lawmakers are advancing a consumer-protection bill tied to crypto kiosks that could force hardware wallet pr...
The median age for first-time buyers climbed to a record 40, with Zillow’s chief executive warning relief from high c...
Anchorage Digital announces a historic custody milestone, expanding regulated access to Tron assets for institutional...
A bold HOA reform in Georgia aims to curb excesses, protect buyers, and sharpen lender risk assessments. This could c...
As 2026 unfolds, lenders tighten credit norms while demand for housing eases. The median approved borrower's credit s...
This article breaks down United Parks PRKS 2026 Q1 earnings, highlighting revenue growth, margins, and the drivers sh...
Institutional investors are loading up on two beaten-down software giants as AI infrastructure demand remains solid a...
B&G Foods' Q1 2026 earnings set the stage for a cautious yet encouraging year. This guide breaks down the drivers, ri...